It is a small molecule able to abrogate STAT3 signaling, for which it is possible to account 22 different clinical trials (phase I/II and III) in which it is used alone or in combination with other chemotherapeutic agents mainly to treat pancreatic, colorectal cancer and glioblastoma (94). Here, STAT3 is linked to glioblastoma.